adplus-dvertising
Connect with us

Business

EU regulator declares AstraZeneca vaccine safe, but experts fear damage has been done – CNN

Published

 on


The European Medicines Agency (EMA)’s executive director Emer Cooke said the agency had “come to a clear scientific conclusion: this is a safe and effective vaccine.”
Cooke said the group did not find that the vaccine causes clotting, though it could not rule out definitively a link to a rare blood clotting disorder, of which seven cases have been reported out of several million doses given. She said the benefits of using the vaccine outweighed the risk.
The committee “concluded that the vaccine is not associated with an increase in the overall risk of thromboembolic events, or blood clots,” Cooke said.
The agency’s decision comes after more than a dozen European countries halted their use of the vaccine, citing reports of a handful of patients across Europe who developed clotting after being inoculated.
Most of the countries said they would await the EMA’s green light before resuming rollouts, but concerns remain about the impact of the suspensions on vaccine hesitancy across the continent.
“I want to reiterate that our scientific position is this: this vaccine is a safe and effective option to protect citizens against Covid-19,” Cooke said at a press conference Thursday.
“It demonstrated that at least 60% efficacy in clinical trials and preventing coronavirus disease, and in fact the real world evidence suggests that the effectiveness could be even higher than that.”
The group said it recommended raising awareness of blood clot reports so that they could be further analyzed. But they said those reports were rare, and that more than 7 million people have received the vaccine in the EU.
Virtually all of western Europe had temporarily stopped using the shot in recent days, even amid a third wave of coronavirus infections across the region, after a small number of reports of clots emerged.
The death of a person in Austria, a woman in Denmark and a third patient in Norway sparked the suspensions. But the decisions were criticized by much of the medical community, and other countries continued to back the use of the vaccine — including the UK, which has given out more than 11 million AstraZeneca doses so far.
In the EU, leaders will now face the question of how to rebuild any trust in the AstraZeneca vaccine that has been lost over the past week. The bloc’s rollout of the jab has stumbled from one obstacle to another since it was approved for use in January, with governments scrambling to secure limited supplies of the jab while simultaneously casting doubts over its efficacy and safety.
Italy, France, Spain, Germany, Cyprus, the Netherlands all announced plans to resume AstraZeneca vaccinations on Friday, with other countries expected to follow. Milan’s largest vaccine center told CNN it would overbook appointments in an attempt to make up for the shortfalls of the past few days.
Ireland’s Prime Minister had earlier told CNN he hoped his country could “catch up fairly quickly” once the vaccination program resumed.
But experts fear that some damage has already been done. In France, an Elabe poll showed this week that only 22% of the population now trusts the AstraZeneca vaccine. Remi Salomon, a senior French hospitals official, told BFM TV on Thursday that “people are being overly cautious” in the country and that he feared “people will not interpret” the suspensions in “the right way.”
“A scare like this has the potential to increase vaccine hesitancy,” Michael Head, senior research fellow in Global Health at the University of Southampton in Britain, told CNN earlier in the week. “These vaccines are to protect against a pandemic virus. There is an urgency to the rollout.”

Nations prepare to restart their rollouts

The EMA did not explicitly advise countries to resume their rollouts, though most have indicated they would do so if the agency reached this conclusion.
But Cooke noted during Thursday’s press conference that “a lot of member states are waiting for this outcome,” and said the conclusions would allow those countries to “make informed decisions.”
And in some European countries, the clamor to make up for lost time began immediately.
“We must resume vaccination as quickly as possible,” Michel Chassang, a French GP and president of the Confederation Of French Medical Trade Unions, told BFM after the EMA announcement.
“The only way to stop the circulation of this virus is precisely to make sure people are vaccinated,” he said, admitting that a loss of confidence in the vaccine could hamper those efforts. “It won’t be easy, we will swim against the tide, because this vaccine (has) now got bad press … and even since the start.”
Its rollout on the continent has been affected by myriad problems; several countries cast doubts over whether it was effective in older people last month, before subsequently concluding that it was.
The EU has also been involved in a tug-of-war over limited supplies after AstraZeneca said it was unable to deliver its full amount of promised supplies; Italy blocked exports of the shot to Australia just days before suspending its rollout.
Italy was the first country to announce it would restart vaccinations after the EMA’s briefing. “The reasons behind the precautionary ban on the use of vaccine batches, issued on March 15, 2021, no longer exist,” its regulatory agency said.
In the UK, which is well ahead of the European bloc in administering doses, Prime Minister Boris Johnson said he would himself be getting the AstraZeneca vaccine on Friday.
Speaking at the UK’s daily Covid-19 briefing, Johnson said the EMA’s verdict was “very important for our European friends.”
“The Oxford jab is safe and the Pfizer jab is safe — the thing that isn’t safe is catching Covid,” he added. “People should continue to get their vaccine when asked to do so.”
Shortly before the EMA’s announcement, Britain’s regulatory agency ruled that “the available evidence does not suggest” the vaccine caused clotting. It said it will continue to review five reports of blood clots in the country, out of more than 11 million people it had vaccinated.
“There is no evidence that that blood clots in veins is occurring more than would be expected in the absence of vaccination, for either vaccine,” MHRA chief executive June Raine said, referring to the Pfizer vaccine which the UK is also rolling out.
AstraZeneca has itself repeatedly insisted its product is safe.
Real-world data from the UK, where far more doses have been given, has shown that it is already having an impact there; a single dose of the vaccine reduced the risk of hospitalization from Covid-19 by more than 80% in people aged over 80, data from Public Health England showed earlier this month. The vaccine is given in two doses, though countries differ in how far apart they are spreading those shots.
Cooke cited such data during the briefing, calling the vaccine “a safe and effective option to protect citizens against Covid-19.”
There is “no increase in overall risk of blood clots” with the AstraZeneca vaccine,” added Dr. Sabine Straus, chair of the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC).
AstraZeneca isn’t the only vaccine available in Europe. Doses of the BioNTech-Pfizer and Moderna vaccines are currently being rolled out to Europeans, while the first deliveries of the Johnson & Johnson vaccine aren’t expected to arrive until mid-April. On Tuesday, Pfizer agreed to accelerate delivery of 10 million doses of its Covid-19 vaccine to the EU, days after AstraZeneca said it would have a “shortfall” in planned vaccine shipments to the bloc.

How rare are the reports of clotting?

More than a dozen countries stopped using the AstraZeneca vaccine following a handful of reports, which began emerging when a woman in Austria died last week.
But those reports were very rare, the EMA confirmed on Thursday. There were seven reports of blood clots in multiple blood vessels (known as disseminated intravascular coagulation, or DIC) and another 18 reports of clots in the vessels draining blood from the brain (CVST)
The overall number of reports of any clotting event after vaccination, either in studies before licensing and during the rollouts, was 469, with 191 of those occurring in the EU. That number too was “lower than that expected in the general population,” the EMA said.
“The Committee was of the opinion that the vaccine’s proven efficacy in preventing hospitalisation and death from COVID-19 outweighs the extremely small likelihood of developing DIC or CVST,” they concluded.
The agency noted there “have been very rare cases of unusual blood clots accompanied by low levels of blood platelets” after vaccination. Those cases “were almost all in women under 55,” they said.
Health experts have been virtually unanimous during the week that the reports were very infrequent, and many expressed surprise when EU countries stopped using the vaccine.
“The numbers involved are tiny, and also probably no more than you would expect in a population anyway,” Jon Gibbins, director of the Institute for Cardiovascular and Metabolic Research at the University of Reading, told CNN earlier this week.
“When you then start immunizing millions of people, it’s inevitable this is going to happen every now and again,” Gibbins said. “But it doesn’t demonstrate causality, it doesn’t demonstrate that the vaccine is actually responsible.”

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Telus prioritizing ‘most important customers,’ avoiding ‘unprofitable’ offers: CFO

Published

 on

 

Telus Corp. says it is avoiding offering “unprofitable” discounts as fierce competition in the Canadian telecommunications sector shows no sign of slowing down.

The company said Friday it had fewer net new customers during its third quarter compared with the same time last year, as it copes with increasingly “aggressive marketing and promotional pricing” that is prompting more customers to switch providers.

Telus said it added 347,000 net new customers, down around 14.5 per cent compared with last year. The figure includes 130,000 mobile phone subscribers and 34,000 internet customers, down 30,000 and 3,000, respectively, year-over-year.

The company reported its mobile phone churn rate — a metric measuring subscribers who cancelled their services — was 1.09 per cent in the third quarter, up from 1.03 per cent in the third quarter of 2023. That included a postpaid mobile phone churn rate of 0.90 per cent in its latest quarter.

Telus said its focus is on customer retention through its “industry-leading service and network quality, along with successful promotions and bundled offerings.”

“The customers we have are the most important customers we can get,” said chief financial officer Doug French in an interview.

“We’ve, again, just continued to focus on what matters most to our customers, from a product and customer service perspective, while not loading unprofitable customers.”

Meanwhile, Telus reported its net income attributable to common shares more than doubled during its third quarter.

The telecommunications company said it earned $280 million, up 105.9 per cent from the same three-month period in 2023. Earnings per diluted share for the quarter ended Sept. 30 was 19 cents compared with nine cents a year earlier.

It reported adjusted net income was $413 million, up 10.7 per cent year-over-year from $373 million in the same quarter last year. Operating revenue and other income for the quarter was $5.1 billion, up 1.8 per cent from the previous year.

Mobile phone average revenue per user was $58.85 in the third quarter, a decrease of $2.09 or 3.4 per cent from a year ago. Telus said the drop was attributable to customers signing up for base rate plans with lower prices, along with a decline in overage and roaming revenues.

It said customers are increasingly adopting unlimited data and Canada-U.S. plans which provide higher and more stable ARPU on a monthly basis.

“In a tough operating environment and relative to peers, we view Q3 results that were in line to slightly better than forecast as the best of the bunch,” said RBC analyst Drew McReynolds in a note.

Scotiabank analyst Maher Yaghi added that “the telecom industry in Canada remains very challenging for all players, however, Telus has been able to face these pressures” and still deliver growth.

The Big 3 telecom providers — which also include Rogers Communications Inc. and BCE Inc. — have frequently stressed that the market has grown more competitive in recent years, especially after the closing of Quebecor Inc.’s purchase of Freedom Mobile in April 2023.

Hailed as a fourth national carrier, Quebecor has invested in enhancements to Freedom’s network while offering more affordable plans as part of a set of commitments it was mandated by Ottawa to agree to.

The cost of telephone services in September was down eight per cent compared with a year earlier, according to Statistics Canada’s most recent inflation report last month.

“I think competition has been and continues to be, I’d say, quite intense in Canada, and we’ve obviously had to just manage our business the way we see fit,” said French.

Asked how long that environment could last, he said that’s out of Telus’ hands.

“What I can control, though, is how we go to market and how we lead with our products,” he said.

“I think the conditions within the market will have to adjust accordingly over time. We’ve continued to focus on digitization, continued to bring our cost structure down to compete, irrespective of the price and the current market conditions.”

Still, Canada’s telecom regulator continues to warn providers about customers facing more charges on their cellphone and internet bills.

On Tuesday, CRTC vice-president of consumer, analytics and strategy Scott Hutton called on providers to ensure they clearly inform their customers of charges such as early cancellation fees.

That followed statements from the regulator in recent weeks cautioning against rising international roaming fees and “surprise” price increases being found on their bills.

Hutton said the CRTC plans to launch public consultations in the coming weeks that will focus “on ensuring that information is clear and consistent, making it easier to compare offers and switch services or providers.”

“The CRTC is concerned with recent trends, which suggest that Canadians may not be benefiting from the full protections of our codes,” he said.

“We will continue to monitor developments and will take further action if our codes are not being followed.”

French said any initiative to boost transparency is a step in the right direction.

“I can’t say we are perfect across the board, but what I can say is we are absolutely taking it under consideration and trying to be the best at communicating with our customers,” he said.

“I think everyone looking in the mirror would say there’s room for improvement.”

This report by The Canadian Press was first published Nov. 8, 2024.

Companies in this story: (TSX:T)

Source link

Continue Reading

Business

TC Energy cuts cost estimate for Southeast Gateway pipeline project in Mexico

Published

 on

 

CALGARY – TC Energy Corp. has lowered the estimated cost of its Southeast Gateway pipeline project in Mexico.

It says it now expects the project to cost between US$3.9 billion and US$4.1 billion compared with its original estimate of US$4.5 billion.

The change came as the company reported a third-quarter profit attributable to common shareholders of C$1.46 billion or $1.40 per share compared with a loss of C$197 million or 19 cents per share in the same quarter last year.

Revenue for the quarter ended Sept. 30 totalled C$4.08 billion, up from C$3.94 billion in the third quarter of 2023.

TC Energy says its comparable earnings for its latest quarter amounted to C$1.03 per share compared with C$1.00 per share a year earlier.

The average analyst estimate had been for a profit of 95 cents per share, according to LSEG Data & Analytics.

This report by The Canadian Press was first published Nov. 7, 2024.

Companies in this story: (TSX:TRP)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

BCE reports Q3 loss on asset impairment charge, cuts revenue guidance

Published

 on

 

BCE Inc. reported a loss in its latest quarter as it recorded $2.11 billion in asset impairment charges, mainly related to Bell Media’s TV and radio properties.

The company says its net loss attributable to common shareholders amounted to $1.24 billion or $1.36 per share for the quarter ended Sept. 30 compared with a profit of $640 million or 70 cents per share a year earlier.

On an adjusted basis, BCE says it earned 75 cents per share in its latest quarter compared with an adjusted profit of 81 cents per share in the same quarter last year.

“Bell’s results for the third quarter demonstrate that we are disciplined in our pursuit of profitable growth in an intensely competitive environment,” BCE chief executive Mirko Bibic said in a statement.

“Our focus this quarter, and throughout 2024, has been to attract higher-margin subscribers and reduce costs to help offset short-term revenue impacts from sustained competitive pricing pressures, slow economic growth and a media advertising market that is in transition.”

Operating revenue for the quarter totalled $5.97 billion, down from $6.08 billion in its third quarter of 2023.

BCE also said it now expects its revenue for 2024 to fall about 1.5 per cent compared with earlier guidance for an increase of zero to four per cent.

The company says the change comes as it faces lower-than-anticipated wireless product revenue and sustained pressure on wireless prices.

BCE added 33,111 net postpaid mobile phone subscribers, down 76.8 per cent from the same period last year, which was the company’s second-best performance on the metric since 2010.

It says the drop was driven by higher customer churn — a measure of subscribers who cancelled their service — amid greater competitive activity and promotional offer intensity. BCE’s monthly churn rate for the category was 1.28 per cent, up from 1.1 per cent during its previous third quarter.

The company also saw 11.6 per cent fewer gross subscriber activations “due to more targeted promotional offers and mobile device discounting compared to last year.”

Bell’s wireless mobile phone average revenue per user was $58.26, down 3.4 per cent from $60.28 in the third quarter of the prior year.

This report by The Canadian Press was first published Nov. 7, 2024.

Companies in this story: (TSX:BCE)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending